1,300 Cancer Medicines and Vaccines In Development
In the last 30 years, significant progress has been made in the fight against cancer. To continue the progress and deliver hope to those battling cancer, biopharmaceutical research companies are working to develop more effective and better-tolerated treatments state the Medicines in Development for Cancer 2020 Report published on December 14, 2020.
Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by the U.S. FDA.
Examples of the science behind potential new cancer treatments include CAR-T therapy, which is intended to permanently alter a patient's T-cells to multiply in the body into an army to recognize and fight the root cause of disease; Gene editing, which is a technique involving the alteration of genes to correct mutations, introduce new genetic information or remove specific DNA sequences; RNA interference and antisense RNA, which are relatively new areas of research and build on a pathway that uses DNA sequence to turn the gene off or modify the gene's expression; and Tumor agnostic therapies, which are treatments based on the molecular markers of the tumor, such as a specific genetic mutation, rather than where the tumor originated in the body.